The diagnosis/prognosis of breast cancer is reliant on conventional techniques common to mammography, CT and MRI; however, following biopsy, the detection of CEA (Carcinoembryonic Tumor Marker) and CA15-3 (Carcinoma Antigen 15-3) or different biomarkers such as Her2 (human epidermal growth factor receptor-2) and CK5 (cytokeratin-5) are required. Here, ERBB2 is linked to carcinoma.